Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 9.0 0.11% 0.01
BCRX closed up 0.11 percent on Friday, February 15, 2019, on 1.59 times normal volume.

Earnings due: Feb 26

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Flat
See historical BCRX trend table...

Date Alert Name Type % Chg
Feb 15 20 DMA Support Bullish 0.00%
Feb 15 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Feb 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Feb 15 Pocket Pivot Bullish Swing Setup 0.00%
Feb 15 Bollinger Band Squeeze Range Contraction 0.00%
Feb 15 Inside Day Range Contraction 0.00%
Feb 14 Crossed Above 20 DMA Bullish 0.11%
Feb 14 1,2,3 Pullback Bullish Bullish Swing Setup 0.11%
Feb 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.11%
Feb 14 Bollinger Band Squeeze Range Contraction 0.11%

Older signals for BCRX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Chemistry Biotechnology Diseases Chemical Compounds Enzymes Gout Seasonal Influenza Acetamides
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.95
52 Week Low 4.53
Average Volume 703,350
200-Day Moving Average 7.207
50-Day Moving Average 8.6244
20-Day Moving Average 8.9725
10-Day Moving Average 9.014
Average True Range 0.4621
ADX 31.23
+DI 22.9295
-DI 11.6572
Chandelier Exit (Long, 3 ATRs ) 8.563699999999999
Chandelier Exit (Short, 3 ATRs ) 9.586299999999999
Upper Bollinger Band 9.5172
Lower Bollinger Band 8.4278
Percent B (%b) 0.53
BandWidth 12.141544
MACD Line 0.1088
MACD Signal Line 0.1262
MACD Histogram -0.0174
Fundamentals Value
Market Cap 723.85 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -14.52
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.47
Resistance 3 (R3) 9.47 9.31 9.39
Resistance 2 (R2) 9.31 9.19 9.31 9.36
Resistance 1 (R1) 9.16 9.12 9.16 9.16 9.34
Pivot Point 9.00 9.00 9.00 9.00 9.00
Support 1 (S1) 8.85 8.88 8.85 8.85 8.66
Support 2 (S2) 8.69 8.81 8.69 8.64
Support 3 (S3) 8.54 8.69 8.61
Support 4 (S4) 8.54